Frontiers in Oncology (Jan 2022)

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation

  • Valentín Ortiz-Maldonado,
  • Valentín Ortiz-Maldonado,
  • Gerard Frigola,
  • Marta Español-Rego,
  • Olga Balagué,
  • Olga Balagué,
  • Nuria Martínez-Cibrián,
  • Laura Magnano,
  • Laura Magnano,
  • Eva Giné,
  • Eva Giné,
  • Eva Giné,
  • Mariona Pascal,
  • Juan G. Correa,
  • Alexandra Martínez-Roca,
  • Joan Cid,
  • Joan Cid,
  • Miquel Lozano,
  • Miquel Lozano,
  • Miquel Lozano,
  • Neus Villamor,
  • Neus Villamor,
  • Neus Villamor,
  • Daniel Benítez-Ribas,
  • Daniel Benítez-Ribas,
  • Jordi Esteve,
  • Jordi Esteve,
  • Jordi Esteve,
  • Jordi Esteve,
  • Armando López-Guillermo,
  • Armando López-Guillermo,
  • Armando López-Guillermo,
  • Armando López-Guillermo,
  • Elías Campo,
  • Elías Campo,
  • Elías Campo,
  • Elías Campo,
  • Elías Campo,
  • Álvaro Urbano-Ispizua,
  • Álvaro Urbano-Ispizua,
  • Álvaro Urbano-Ispizua,
  • Álvaro Urbano-Ispizua,
  • Manel Juan,
  • Manel Juan,
  • Manel Juan,
  • Julio Delgado,
  • Julio Delgado,
  • Julio Delgado,
  • Julio Delgado

DOI
https://doi.org/10.3389/fonc.2022.828471
Journal volume & issue
Vol. 12

Abstract

Read online

CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high-risk CLL or RT.

Keywords